ARVN Stock News & Analysis | Latest Updates

Arvinas to Participate in Upcoming Investor Conferences

(NASDAQ:ARVN) NEW HAVEN, Conn., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in fireside chats at two upcoming investor conferences:

August 29, 2025Investor

ARVN News

Arvinas to Participate in Upcoming Investor Conferences

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

Pfizer, Arvinas Partnered Breast Cancer Drug Cuts Progression Risk By 43% In Trial, Seeks FDA Approval

Arvinas Submits NDA To FDA With Partner Pfizer For Vepdegestrant For Treatment Of Patients With ER+/HER2- ESR1-Mutated Advanced Or Metastatic Breast Cancer Previously Treated With Endocrine-Based Therapy

Arvinas To Present New Preclinical Data For ARV-393 At European Hematology Association Meeting

What Analysts Are Saying About Arvinas Stock

SAIC, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Leerink Partners Downgrades Arvinas to Market Perform, Lowers Price Target to $9

Reported Saturday, Arvinas and Pfizer's Vepdegestrant Demonstrates Statistically Significant 2.9-Month PFS Benefit Over Fulvestrant In ESR1-Mutant Second-Line Advanced Breast Cancer

Watching Arvinas; Traders Circulate Zacks Under $10 Newsletter Picks Stock

UBS Maintains Buy on Arvinas, Lowers Price Target to $21

Morgan Stanley Maintains Equal-Weight on Arvinas, Lowers Price Target to $11

Citigroup Maintains Neutral on Arvinas, Lowers Price Target to $9.5

Where Arvinas Stands With Analysts

Truist Securities Downgrades Arvinas to Hold, Lowers Price Target to $11

BMO Capital Maintains Outperform on Arvinas, Lowers Price Target to $10

Wells Fargo Maintains Overweight on Arvinas, Lowers Price Target to $19

Goldman Sachs Maintains Neutral on Arvinas, Lowers Price Target to $8

Guggenheim Maintains Buy on Arvinas, Lowers Price Target to $16

Piper Sandler Reiterates Overweight on Arvinas, Lowers Price Target to $14

Barclays Maintains Overweight on Arvinas, Lowers Price Target to $16

HC Wainwright & Co. Maintains Buy on Arvinas, Lowers Price Target to $24

Jefferies Downgrades Arvinas to Hold, Lowers Price Target to $10

Dow Surges Over 300 Points; McDonald's Posts Weak Revenue

12 Health Care Stocks Moving In Thursday's Intraday Session

Nasdaq Jumps 1.5%; Microsoft Posts Upbeat Results

Arvinas Q1 GAAP EPS $1.14 and Sales $188.80M.

A Peek at Arvinas's Future Earnings

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Arvinas Reports Preclinical Results for New Lymphoma Drug Combo at Cancer Research Meeting

Arvinas Announced That New Preclinical Combination Data For ARV-393 Will Be Presented At The American Association For Cancer Research Annual Meeting

Goldman Sachs Maintains Neutral on Arvinas, Lowers Price Target to $12

Truist Securities Maintains Buy on Arvinas, Lowers Price Target to $21

HC Wainwright & Co. Reiterates Buy on Arvinas, Maintains $81 Price Target

Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study

Arvinas Says It Presented First-in-Human Data For Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, And Central And Peripheral LRRK2 Degradation

Top 3 Health Care Stocks That Are Set To Fly This Month

HC Wainwright & Co. Reiterates Buy on Arvinas, Maintains $81 Price Target

Morgan Stanley Maintains Equal-Weight on Arvinas, Lowers Price Target to $12

Guggenheim Maintains Buy on Arvinas, Lowers Price Target to $32

Wells Fargo Maintains Overweight on Arvinas, Lowers Price Target to $26

Tesla To $120? Here Are 10 Top Analyst Forecasts For Wednesday

This PepsiCo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Wedbush Downgrades Arvinas to Neutral, Lowers Price Target to $12

B of A Securities Maintains Buy on Arvinas, Lowers Price Target to $28

Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial

Crude Oil Gains 1%; Ciena Earnings Top Views

HC Wainwright & Co. Reiterates Buy on Arvinas, Maintains $81 Price Target

US Stocks Mixed; Kohl's Shares Plunge After Q4 Results

Arvinas And Pfizer Announced Topline Results From The Phase 3 VERITAC-2 Trial Of Vepdegestrant Monotherapy Versus Fulvestrant In Adults With Advanced Or Metastatic Breast Cancer, The Trial Met Its Primary Endpoint Demonstrating A Statistically Significant